News Cardiol Therapeutics Inc.

Stocks

CRDL

CA14161Y2006

Biotechnology & Medical Research

Market Closed - Toronto S.E. 16:00:00 2026-09-18 EDT			5-day change	1st Jan Change
2.610 ^CAD	-1.14%		-5.09%	+99.24%

08-12	Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-11	Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

All News

Mentions Relevance

09-16	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds	PR
09-16	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds	AQ
09-10	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission	PR
09-10	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission	AQ
09-09	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference	PR
09-09	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-12	Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-05	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	PR
08-05	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	AQ
07-14	Cardiol Therapeutics : rsquo; Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PU
07-14	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PR
07-14	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	AQ
07-09	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	PR
07-09	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	AQ
06-25	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	PR
06-25	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	AQ
06-23	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	PR
06-23	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	AQ
05-14	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	PR
05-14	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	AQ
05-11	Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment	MT
05-07	Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis	MT
05-07	Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association	MT
05-07	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	PR